Prostate cancer is a hormone-dependent disease that relies on androgens to advance and proliferate.¹ Approximately 95% of circulating androgens come from testicular production.²

However, androgens are also produced by the adrenal glands (approximately 5%).²

Luteinizing hormone-releasing hormone analogs (LHRH-As) suppress testicular production of androgens to castrate levels.^{1, 2}

Nonsteroidal antiandrogens (NSAAs) block the binding of androgens at the receptor site.^{1, 2}

NSAAs, such as CASODEX 50 mg Tablets, when used with an LHRH-A as part of CAB therapy, help inhibit the growth of prostate cancer cells.^{2, 3}

CASODEX 50 mg daily is indicated for use in combination therapy with a luteinizing hormone-releasing hormone (LHRH) analog for the treatment of Stage D2 metastatic carcinoma of the prostate.

CASODEX 150 mg daily is not approved for use alone or with other treatments. See "CLINICAL PHARMACOLOGY-Clinical Studies-Safety Data from Clinical Studies using CASODEX 150 mg" section in the full Prescribing Information for additional important safety information regarding CASODEX 150 mg.³

In a randomized, double-blind (for antiandrogen therapy only) study in 813 patients with untreated metastatic prostate cancer (CASODEX plus LHRH-A, n=404; flutamide plus LHRH-A, n=409)^3,4:

• Median duration of treatment was 72 weeks (504 days) with CASODEX plus LHRH-A therapy and 59 weeks (413 days) with flutamide plus LHRH-A therapy^3,4



• Median survival time was 180 weeks with CASODEX plus LHRH-A therapy compared with 148 weeks with flutamide plus LHRH-A therapy (P =0.15)^3,4







• Median time to progression was 97 weeks in patients treated with CASODEX plus an LHRH-A and 77 weeks in patients treated with flutamide plus an LHRH-A (P=0.41)^3,4

CASODEX 50 mg daily is indicated for use in combination therapy with a luteinizing hormone-releasing hormone (LHRH) analog for the treatment of Stage D2 metastatic carcinoma of the prostate.

CASODEX 150 mg daily is not approved for use alone or with other treatments. See "CLINICAL PHARMACOLOGY-Clinical Studies-Safety Data from Clinical Studies using CASODEX 150 mg" section in the full Prescribing Information for additional important safety information regarding CASODEX 150 mg.³

References:

1. Garnick MB. Prostate cancer: screening, diagnosis, and management. Ann Intern Med. 1993;118:804-818.
   
   
2. Vogelzang NJ, Shipley WU, Scardino PT, Coffey DS, eds. Comprehensive Textbook of Genitourinary Oncology. 2nd ed. Philadelphia, Pa: Lippincott Williams & Wilkins; 2000.
   
   
3. CASODEX® (bicalutamide) 50 mg Tablets full Prescribing Information, AstraZeneca Pharmaceuticals LP, Wilmington, Delaware.
   
   
4. Schellhammer PF, Sharifi R, Block NL, et al. Clinical benefits of bicalutamide compared with flutamide in combined androgen blockade for patients with advanced prostatic carcinoma: final report of a double-blind, randomized, multicenter trial. Urology. 1997;50:330-336.